Altimmune Stock

Altimmune Stock-Based Compensation

The Stock-Based Compensation (SBC) of Altimmune (ALT) as of Aug 8, 2026 is 16.08 M USD. In the previous year, Stock-Based Compensation (SBC) was 14.39 M USD — a change of 11.69% (higher).

Stock-Based Compensation

16.08 MUSD

YoY

11.69%

Last updated:

Stock-Based Compensation (SBC) of Altimmune is 2026 16.08 M USD. Stock-Based Compensation (SBC) of Altimmune was 2025 14.39 M USD. It decreases by 11.69% higher compared to the previous year.
Access this data via the Eulerpool API

Altimmune Stock analysis

What does Altimmune do? Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Altimmune stock

Stock-Based Compensation (SBC) of Altimmune is 16.08 M USD in 2026.

Stock-Based Compensation (SBC) of Altimmune changed from 14.39 M USD to 16.08 M USD, representing a 11.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Altimmune since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Altimmune historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Altimmune

All Key Metrics — Altimmune